NCT02135874View on ClinicalTrials.gov

Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 27, 2014

Primary Completion Date

February 21, 2023

Study Completion Date

February 21, 2023

Conditions
Acute Bilineal LeukemiaAcute Biphenotypic LeukemiaAcute Leukemia of Ambiguous LineageAcute Undifferentiated LeukemiaMixed Phenotype Acute LeukemiaMixed Phenotype Acute Leukemia, B/Myeloid, Not Otherwise SpecifiedMixed Phenotype Acute Leukemia, T/Myeloid, Not Otherwise SpecifiedRecurrent Mixed Phenotype Acute Leukemia
Interventions
DRUG

Clofarabine

Given IV

DRUG

Cytarabine

Given IV

DRUG

Dexamethasone

Given IV

DRUG

Idarubicin

Given IV

BIOLOGICAL

Rituximab

Given IV

DRUG

Sorafenib

Given PO

DRUG

Sorafenib Tosylate

Given PO

DRUG

Vincristine

Given IV

DRUG

Vincristine Sulfate

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT02135874 - Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia | Biotech Hunter | Biotech Hunter